Key clinical point: Tisotumab vedotin shows encouraging activity and tolerability in heavily pretreated recurrent or metastatic cervical cancer.
Major finding: ORR in 55 cervical cancer patients was 35%, confirmed ORR was 22%.
Study details: A phase 1/2a expansion study of 55 patients
Disclosures: The innovaTV 201 trial is sponsored by Genmab A/S. Dr. Hong reported having no disclosures.
Hong DS et al. SGO 2019, Abstract 19.